Allspring Global Investments Holdings LLC Decreases Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Allspring Global Investments Holdings LLC lessened its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 35.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 89,920 shares of the company’s stock after selling 50,353 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Nurix Therapeutics were worth $1,694,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Sumitomo Mitsui Trust Group Inc. acquired a new position in shares of Nurix Therapeutics during the 3rd quarter worth about $12,432,000. FMR LLC lifted its stake in Nurix Therapeutics by 675.9% during the third quarter. FMR LLC now owns 586,902 shares of the company’s stock worth $13,188,000 after purchasing an additional 511,256 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in Nurix Therapeutics during the third quarter worth approximately $7,879,000. Patient Square Capital LP acquired a new position in Nurix Therapeutics in the third quarter valued at approximately $7,320,000. Finally, Wellington Management Group LLP increased its stake in Nurix Therapeutics by 8.8% in the third quarter. Wellington Management Group LLP now owns 3,482,105 shares of the company’s stock valued at $78,243,000 after purchasing an additional 280,240 shares during the last quarter.

Nurix Therapeutics Price Performance

NASDAQ:NRIX opened at $16.87 on Friday. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -5.84 and a beta of 2.14. The firm’s fifty day moving average price is $19.05 and its 200 day moving average price is $22.00. Nurix Therapeutics, Inc. has a 1-year low of $9.91 and a 1-year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. As a group, analysts expect that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 2,811 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the sale, the chief financial officer now owns 39,549 shares in the company, valued at $785,047.65. The trade was a 6.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on NRIX. BMO Capital Markets initiated coverage on shares of Nurix Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $35.00 price objective for the company. BTIG Research started coverage on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $35.00 price target for the company. JPMorgan Chase & Co. decreased their price objective on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Royal Bank of Canada lifted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Finally, Needham & Company LLC dropped their price target on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.81.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.